Max Ratnikov, Ph.D.

Maxim Ratnikov is a medicinal chemist and product leader in drug discovery, currently Senior Product Manager at Deep Origin. He brings extensive experience spanning structure-based and phenotypic discovery, AI/ML-driven design, lab automation, ADME/PK, and computational chemistry, built through roles at Novartis, Strateos, and Calibr–Skaggs Institute for Innovative Medicines. At Novartis, he co-designed the oral small-molecule clinical candidate LXE408 for visceral leishmaniasis and contributed to additional clinical programs in regenerative medicine and oncology. At Strateos, he led automated synthesis platform development and advanced AI-enabled tools for virtual screening, docking, retrosynthesis, and ADME prediction. Maxim holds a PhD in Organic Chemistry from the University of Maryland and completed postdoctoral research at Scripps Research.